尼妥珠单抗联合表阿霉素对人肝癌细胞株ＨｅｐＧ２体外生长的影响

目的　观察尼妥珠单抗（ｈ-Ｒ３）与表阿霉素（ＥＰＩ）联合对人肝癌细胞株ＨｅｐＧ２体外生长及凋亡的影响。方法　选用浓度递增的ｈ-Ｒ３和ＥＰＩ，单独和联合作用于ＨｅｐＧ２细胞，ＭＴＴ法观察不同时间点、不同药物剂量对ＨｅｐＧ２细胞生长的影响，计算两者联合的ｑ值；流式细胞仪检测两种药物对ＨｅｐＧ２细胞凋亡率及细胞周期分布情况的影响。结果　ｈ-Ｒ３和ＥＰＩ单药对ＨｅｐＧ２细胞生长均有抑制作用且呈时间和剂量依赖性，两药单独作用７２ｈ后对ＨｅｐＧ２细胞生长的最高抑制率分别为（４９.５６±８.９３）％和（９２.９７±１.１９）％，两药联合对ＨｅｐＧ２细胞生长的最高抑制率为（６.４４±１.０）％，联合用药可提高细胞增殖抑制率，呈相加作用；流式细胞仪检测发现，联合组细胞凋亡率高于单药组，随时间增加凋亡率呈升高趋势；细胞周期检测提示ｈ-Ｒ３使细胞阻滞在Ｇ０／Ｇ１期，ＥＰＩ阻滞细胞在Ｓ期，两药均能影响细胞周期分布。结论　ｈ- Ｒ３在体外与ＥＰＩ联合可以提高对ＨｅｐＧ２细胞增殖抑制及凋亡的作用，两药均可影响ＨｅｐＧ２细胞周期的分布。

The effect of epirubici combined with nimotuzumab on human hepatocellular carcinoma cell line HepG2 in vitro

Objective To investigate the anti-proliferation effect of epidermal growth factor receptor inhibitor nimotuzumab combined with chemotherapeutic drug epirubici on growth of human hepatocellular carcinoma HepG2 cells.Methods MTT assay was performed to evaluated the growth inhibitory rate of HepG2 cells.Increasing dose of nimotuzumab and epirubici alone or in combination were administrated to HepG2 cells.The inhibitory effects of the drugs on cell proliferation at different time points were observed,and q valu...